Funding sources This study was supported by the National ‘Programme Hospitalier de Recherche Clinique (PHRC) 2006’. We thank the ‘Association Française des Sclérodermiques (AFS)’, the ‘Groupe Français de Recherche sur la Sclérodermie (GFRS)’ and Novartis Pharmaceuticals for giving supplemental support to this study.
Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial
Article first published online: 5 OCT 2012
© 2012 The Authors. BJD © 2012 British Association of Dermatologists
British Journal of Dermatology
Volume 167, Issue 5, pages 1138–1144, November 2012
How to Cite
Prey, S., Ezzedine, K., Doussau, A., Grandoulier, A.-S., Barcat, D., Chatelus, E., Diot, E., Durant, C., Hachulla, E., de Korwin-Krokowski, J.-D., Kostrzewa, E., Quemeneur, T., Paul, C., Schaeverbeke, T., Seneschal, J., Solanilla, A., Sparsa, A., Bouchet, S., Lepreux, S., Mahon, F.-X., Chene, G. and Taïeb, A. (2012), Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial. British Journal of Dermatology, 167: 1138–1144. doi: 10.1111/j.1365-2133.2012.11186.x
Conflicts of interest None declared.
- Issue published online: 29 OCT 2012
- Article first published online: 5 OCT 2012
- Accepted for publication 17 June 2012
Fig S1. Evolution of the modified Health Assessment Questionnaire for Scleroderma at each study visit (month 0, 1, 3, 6 and 12). (a) Patients treated with imatinib mesylate; (b) patients treated with placebo.
Fig S2. Evolution of the patients’ weight at each study visit (month 0, 1, 3, 6 and 12). (a) Patients treated with imatinib mesylate; (b) patients treated with placebo.
Appendix S1. (a) Sensitivity analysis. (b) Summary of investigations after unblinding concerning placebo patients with plasmatic imatinib positive dosage.
|BJD_11186_sm_FigsS1-S2-AppendixS1.doc||93K||Supporting info item|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.